- Home
- / Contineum Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Contineum Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$17.1
2024-10-29
Market Capitalization
$440.1 M
2024-10-29
Revenue
$50 M
FY, 2023
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|
| Revenue | 50.0M | ||
| General and administrative expense | 6.3M | 12.5M | 16.5M |
| Operating expense total | 33.9M | 50.9M | 68.1M |
| EBIT | 16.1M | (50.9M) | (68.1M) |
| EBIT margin, % | 32.2% | ||
| Interest income | 4.6M | 8.9M | 8.2M |
| Interest expense | 208.0K | ||
| Pre tax profit | 23.2M | (42.3M) | |
| Income tax expense | 450.0K | ||
| Net Income | 22.7M | (42.3M) | (60.0M) |
| EPS | 0.1 | (2.2) | (2.2) |